BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang J, Wang C, Chen N, Shu C, Guo X, He Y, Zhou Y. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res 2014;134:1241-8. [PMID: 25450536 DOI: 10.1016/j.thromres.2014.09.035] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Rezus E, Tamba BI, Badescu MC, Popescu D, Bratoiu I, Rezus C. Osteonecrosis of the Femoral Head in Patients with Hypercoagulability-From Pathophysiology to Therapeutic Implications. Int J Mol Sci 2021;22:6801. [PMID: 34202897 DOI: 10.3390/ijms22136801] [Reference Citation Analysis]
2 Cernera G, Di Minno A, Amato F, Elce A, Liguori R, Bruzzese D, Di Lullo AM, Castaldo G, Zarrilli F, Comegna M. Molecular Analysis of Prothrombotic Gene Variants in Venous Thrombosis: A Potential Role for Sex and Thrombotic Localization. J Clin Med 2020;9:E1008. [PMID: 32252449 DOI: 10.3390/jcm9041008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang G, Wang P, Li T, Deng X. Genetic association between plasminogen activator inhibitor-1 rs1799889 polymorphism and venous thromboembolism: Evidence from a comprehensive meta-analysis. Clin Cardiol 2019;42:1232-8. [PMID: 31701558 DOI: 10.1002/clc.23282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Perés Wingeyer S, Aranda F, Udry S, Latino J, de Larrañaga G. Trombofilia hereditaria y pérdidas de embarazo. Estudio de una cohorte de Argentina. Medicina Clínica 2019;152:249-54. [DOI: 10.1016/j.medcli.2017.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Trasca LF, Patrascu N, Bruja R, Munteanu O, Cirstoiu M, Vinereanu D. Therapeutic Implications of Inherited Thrombophilia in Pregnancy. Am J Ther 2019;26:e364-74. [PMID: 30985485 DOI: 10.1097/MJT.0000000000000985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
6 Vesa ŞC, Trifa AP, Crişan S, Buzoianu AD. VKORC1 -1639 G>A Polymorphism in Romanian Patients With Deep Vein Thrombosis. Clin Appl Thromb Hemost 2016;22:760-4. [PMID: 25976278 DOI: 10.1177/1076029615585993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Foley JH, Conway EM. Cross Talk Pathways Between Coagulation and Inflammation. Circ Res 2016;118:1392-408. [PMID: 27126649 DOI: 10.1161/CIRCRESAHA.116.306853] [Cited by in Crossref: 188] [Cited by in F6Publishing: 132] [Article Influence: 37.6] [Reference Citation Analysis]
8 Boersma RS, Hamulyak K, van Oerle R, Tuinenburg A, Ten Cate-Hoek AJ, Schouten HC. Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies. Clin Appl Thromb Hemost 2016;22:779-84. [PMID: 25888571 DOI: 10.1177/1076029615579098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
9 Wang B, Xu P, Shu Q, Yan S, Xu H. Combined Effect of MTHFR C677T and PAI-1 4G/5G Polymorphisms on the Risk of Venous Thromboembolism in Chinese Lung Cancer Patients. Clin Appl Thromb Hemost 2021;27:10760296211031291. [PMID: 34325549 DOI: 10.1177/10760296211031291] [Reference Citation Analysis]
10 Zhang Q, Jin Y, Li X, Peng X, Peng N, Song J, Xu M. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review. Vasa 2020;49:141-6. [DOI: 10.1024/0301-1526/a000839] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
11 Sundquist K, Wang X, Svensson PJ, Sundquist J, Hedelius A, Larsson Lönn S, Zöller B, Memon AA. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence. Thromb Haemost 2015;114:1156-64. [PMID: 26245493 DOI: 10.1160/TH15-01-0031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
12 Falvella FS, Cremolini C, Miceli R, Nichetti F, Cheli S, Antoniotti C, Infante G, Martinetti A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, de Braud F, Di Bartolomeo M, Clementi E, Loupakis F, Pietrantonio F. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics J 2017;17:331-6. [DOI: 10.1038/tpj.2016.22] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Anaya-Macias BU, De la Cruz-Mosso U, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla G, González-López L, Gámez-Nava JI, Pérez-Guerrero EE, Barrientos-Avalos SL, Muñoz-Valle JF. The -675 4G/5G PAI-1 polymorphism confers genetic susceptibility to systemic lupus erythematosus, its clinical manifestations, and comorbidities in Mexican-Mestizo population. Autoimmunity 2020;53:71-7. [PMID: 31829037 DOI: 10.1080/08916934.2019.1700957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]